HOTHHoth Therapeutics Inc
HOTH
Hoth Therapeutics Inc11,640
Mkt Cap
$12.82MVolume
74,226.0052W High
$2.1252W Low
$0.4894PE Ratio
-0.74HOTH Fundamentals
Price
$0.66Prev Close
$0.6701Open
$0.656750D MA
$0.81Beta
1.09Avg. Volume
6.85MEPS (Annual)
-$0.9032P/B
1.69Rev/Employee
$0.00$7.43
Hoth Therapeutics Secures European Authorization in Spain for HT-001 Phase 2a Trial as Interim Data Show Strong Efficacy in Cancer Patients
Hoth Therapeutics Secures European Authorization in Spain for HT-001 Phase 2a Trial as Interim Data Show Strong Efficacy in Cancer Patients Hoth Therapeutics Secures European Authorization in Spain...
PR Newswire·6d ago
Rewriting Fat Itself: Hoth Therapeutics May Be Targeting the Root of Metabolic Disease
Hoth Therapeutics (NASDAQ:HOTH) is stepping into one of the most competitive, and lucrative, arenas in biotech with data that suggests a fundamentally different approach to treating metabolic disease. Rather than simply helping patients lose weight, the company’s latest HT-VA study indicates it may be able to reprogram how the body creates and burns fat at the genetic level.
24-7 Market News·27d ago
Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming Semaglutide
Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming Semaglutide Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down...
PR Newswire·28d ago
Hoth Therapeutics Announces Closing of $2.0 Million Registered Direct Offering
Hoth Therapeutics Announces Closing of $2.0 Million Registered Direct Offering Hoth Therapeutics Announces Closing of $2.0 Million Registered Direct Offering PR Newswire NEW YORK, April 2, 2026 NEW...
PR Newswire·1mo ago
Hoth Therapeutics Announces $2.0 Million Registered Direct Offering
Hoth Therapeutics Announces $2.0 Million Registered Direct Offering Hoth Therapeutics Announces $2.0 Million Registered Direct Offering PR Newswire NEW YORK, April 1, 2026 NEW YORK, April 1, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH), a clinical-stage biopharmaceutical company...
PR Newswire·1mo ago
Hungary Approves Trial Expansion as HT-001 Meets Primary Endpoint in Interim Analysis with Patients Reaching ARIGA 1 by Week Six
Hungary Approves Trial Expansion as HT-001 Meets Primary Endpoint in Interim Analysis with Patients Reaching ARIGA 1 by Week Six Hungary Approves Trial Expansion as HT-001 Meets Primary Endpoint in...
PR Newswire·1mo ago
Hoth Therapeutics Announces Issuance of Chinese Patent for Cancer Cell-Targeting Technology
Hoth Therapeutics Announces Issuance of Chinese Patent for Cancer Cell-Targeting Technology Hoth Therapeutics Announces Issuance of Chinese Patent for Cancer Cell-Targeting Technology PR Newswire NEW...
PR Newswire·1mo ago
Hoth Therapeutics Deploys OpenClaw AI Platform to Accelerate Drug Discovery
Hoth Therapeutics Deploys OpenClaw AI Platform to Accelerate Drug Discovery Hoth Therapeutics Deploys OpenClaw AI Platform to Accelerate Drug Discovery PR Newswire NEW YORK, March 26, 2026 NEW YORK...
PR Newswire·2mo ago
<
1
2
...
>